Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more
Sk Biopharmaceuticals Co Ltd (326030) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.095x
Based on the latest financial reports, Sk Biopharmaceuticals Co Ltd (326030) has a cash flow conversion efficiency ratio of 0.095x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩65.41 Billion) by net assets (₩689.46 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sk Biopharmaceuticals Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Sk Biopharmaceuticals Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sk Biopharmaceuticals Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sk Biopharmaceuticals Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nihon Unisys Ltd
MU:NIU
|
0.059x |
|
Emmi AG
PINK:EMLZF
|
0.154x |
|
CUSTOMERS BANCORP VTG DL1
F:334
|
N/A |
|
Enterprise Financial Services
NASDAQ:EFSC
|
0.024x |
|
Getty Realty Corporation
NYSE:GTY
|
0.030x |
|
Adaro Andalan Indonesia Tbk
JK:AADI
|
0.103x |
|
TietoEVRY Corp
HE:TIETO
|
0.149x |
|
NAGOYA RAILROAD
F:59V
|
N/A |
Annual Cash Flow Conversion Efficiency for Sk Biopharmaceuticals Co Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Sk Biopharmaceuticals Co Ltd from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩573.98 Billion | ₩94.90 Billion | 0.165x | +156.33% |
| 2023-12-31 | ₩320.95 Billion | ₩-94.20 Billion | -0.294x | +41.90% |
| 2022-12-31 | ₩316.56 Billion | ₩-159.92 Billion | -0.505x | -141.62% |
| 2021-12-31 | ₩444.19 Billion | ₩-92.87 Billion | -0.209x | +62.39% |
| 2020-12-31 | ₩379.07 Billion | ₩-210.73 Billion | -0.556x | -108.90% |
| 2019-12-31 | ₩-13.03 Billion | ₩-81.33 Billion | 6.244x | +359.13% |
| 2018-12-31 | ₩58.63 Billion | ₩-141.28 Billion | -2.410x | -15.76% |
| 2017-12-31 | ₩47.24 Billion | ₩-98.34 Billion | -2.082x | -528.17% |
| 2016-12-31 | ₩147.69 Billion | ₩-48.94 Billion | -0.331x | -- |